The Annals Holiday Offer - Save 50%
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 19 October 2004, www.theannals.com, DOI 10.1345/aph.1E143.
 The Annals of Pharmacotherapy: Vol. 38, No. 12, pp. 2145-2149. DOI 10.1345/aph.1E143
© 2004 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow For Our Patients
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Caiola, K.
Right arrow Articles by Cheng, J. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Caiola, K.
Right arrow Articles by Cheng, J. W.

DRUG INFORMATION ROUNDS

Use of Erythropoietin in Heart Failure Management

Krista Caiola, PharmD

at time of writing, Pharmacy Practice Resident, Mount Sinai Hospital, New York, NY; now, Clinical Pharmacist, Mount Sinai Hospital of Queens, New York

Judy WM Cheng, PharmD BCPS FCCP

Associate Professor of Pharmacy Practice, Long Island University, Long Island, NY; Clinical Pharmacy Specialist of Cardiology, Mount Sinai Medical Center

Reprints: Judy WM Cheng PharmD BCPS FCCP, Mount Sinai Medical Center, One Gustave L Levy Pl., Box 1211, New York, NY 10029-6574, fax 212/987-0198, judy.cheng{at}liu.edu

OBJECTIVE: To review the use of erythropoietin for anemia in heart failure (HF).

DATA SOURCES: Peer-reviewed articles in MEDLINE (1966–June 2004) were identified and citations from available articles were reviewed using the search terms anemia, erythropoietin, and heart failure.

DATA SYNTHESIS: Anemia worsens HF prognosis. Clinical studies in patients with New York Heart Association Class III/IV HF who had hemoglobin <12 mg/dL and were refractory to maximal medical management showed that erythropoietin improves symptoms. Larger scale studies with mortality endpoints are required to confirm the benefits.

CONCLUSIONS: In selected patients with severe, chronic HF, erythropoietin may be considered for functional improvement. However, routine use of this treatment strategy is not recommended until more data are available.

Key Words: anemia, erythropoietin, heart failure

Published Online, October 19, 2004. www.theannals.com, DOI 10.1345/aph.1E143




homecopy help contact us subscription past issues search current issue
Copyright © 2004 by Harvey Whitney Books Company.